Shows & Panels
- Accelerate and Streamline for Better Customer Service
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Client Virtualization Solutions
- Data Protection in a Virtual World
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Feds in the Cloud
- Health IT: A Policy Change Agent
- Improving Healthcare Outcomes through IT Policy
- IT Innovation in the New Era of Government
- Making Dollars And Sense Out of Data Center Consolidation
- Navigating the Private Cloud
- One Step to the Cloud, Two Steps Toward Innovation
- Path to FDCCI Compliance
- Take Command of Your Mobility Initiative
Shows & Panels
Vertex drug label to warn on possible fatal rash
Wednesday - 12/19/2012, 2:00pm EST
CAMBRIDGE, Mass. (AP) - The Food and Drug Administration is attaching a black box warning to the Vertex Pharmaceuticals hepatitis C treatment Incivek over a potentially fatal rash.
The FDA says patients taking the pill in combination with two other treatments should stop immediately if they develop a rash that grows worse or comes with symptoms like a fever, diarrhea or mouth sores.
Patients taking this drug can develop a rash that covers more than half the body.
Vertex Pharmaceuticals Inc. says the drug's labeling had already warned that patients with a serious skin reaction should stop. The new warning is much more prominent on the label.
Incivek is taken with the pill ribavirin and interferon, which is given by injection. A black box warning is the most serious form of safety warning.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)